a prospective nationwide study of oncology practice . J Natl Compr Canc Netw 2008 ; 6 : 109 – 118 . 2 Kuderer NM Dale DC Crawford J . Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients . Cancer
Search Results
Impact of Chemotherapy Dose Intensity on Cancer Patient Outcomes
Gary H. Lyman
CLO24-081: Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of Head and Neck–Biweekly Docetaxel, Cisplatin, 5-Fluorouracil, Leucovorin (TPFL) Versus Triweekly TPF: Response Assessment and Translation Into Survival Benefit
Sreevalli Anantharamu, A Sreevalli, Linu Abraham Jacob, Lokanatha Dasappa, Suresh Babu MC, Iokesh KN, Rudresha AH, R. Lakkavalli Krishnappa, and Saldanha Saldanha
%. Among the toxicities grade 3/4 neutropenia was seen in 23.3% vs 41.7% ( P =.05), febrile neutropenia in 6.7% vs 20% ( P =.031). Grade 3/4 mucositis was seen in 5% vs 23.3%( P =.007), grade 3/4 diarrhea in 1.7% vs 10% ( P =.027). Treatment delay and inter
Antimicrobial Stewardship in Cancer Patients: The Time is Now
Samuel L. Aitken, Jerod L. Nagel, Lilian Abbo, William Alegria, Jason N. Barreto, Sanjeet Dadwal, Alison G. Freifeld, Rupali Jain, Steven A. Pergam, Frank P. Tverdek, Susan K. Seo, and on behalf of the Antimicrobial Stewardship in Cancer Consortium ASCC
, immunotherapy). Safety of Antimicrobial De-escalation in Patients With Febrile Neutropenia Retrospective studies suggest that antibiotic de-escalation to fluoroquinolone prophylaxis in patients with febrile neutropenia who have defervesced and remain clinically
New Biosimilar Approvals for Myeloid Growth Factors and Anemia
Gary H. Lyman
The 2019 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hematopoietic Growth Factors include appropriate risk assessment for febrile neutropenia following chemotherapy that is similar to other guidelines in different cancers. In
Long-Term Outcomes of Myeloid Growth Factor Treatment
Gary H. Lyman and David C. Dale
complications, including febrile neutropenia, infection, and infection-related mortality, in patients undergoing cancer chemotherapy, while enabling an increase in delivered chemotherapy dose intensity. 1 , 2 Clinical practice guidelines from NCCN, ASCO, and
Treatment Strategies for Myeloid Growth Factors and Intravenous Iron: When, What, and How?
Jeffrey Crawford and George M. Rodgers
Chemotherapy-induced neutropenia is hazardous for 2 reasons: it produces febrile neutropenia (FN), which may result in life-threatening infections and prolonged hospitalizations, and it can necessitate chemotherapy dose reductions and delays
The Costs of Drugs Used to Treat Myelodysplastic Syndromes Following National Comprehensive Cancer Network Guidelines
Peter L. Greenberg, Leon E. Cosler, Salvatore A. Ferro, and Gary H. Lyman
descriptive review . Nat Clin Pract Oncol 2007 ; 4 : 643 – 656 . 29. Kuderer NM Dale DC Crawford J . Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients . Cancer 2006 ; 106 : 2258 – 2266 . 30
Correspondence
Marc Fishman, William Shimp, James Krook, Akhil Kumar, and William J.M. Hrushesky
alternative choices but rather avoiding use of the drug with chemotherapy regimens with a low risk of febrile neutropenia. 2 , 3 We agree with Dr. Burstein that a serious dialogue on cost-effective care is needed. Talk, however, is clearly not enough. We
The Top Five in Oncology: Where Do We Go From Here?
Harold J. Burstein
. No white cell–stimulating factors for primary prevention of febrile neutropenia for patients with less than 20% risk for this complication. If the ancient adage, “First, do no harm” is still sacred, then the next line would be “Second, do no
Counterpoint: Routine Anti-Bacterial Prophylaxis Is Not Indicated in Neutropenic Patients With Hematological Malignancies
Michael Kleinberg
amikacin as empiric therapy for febrile neutropenia . Clin Infect Dis 2001 ; 33 : 1295 – 1301 . 26 Gomez L Garau J Estrada C . Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of
